The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS

NCT ID: NCT03808402

Last Updated: 2025-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2973 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-26

Study Completion Date

2024-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective observational study using de-identified data from the Neonatal Network Research Database (NNRD) supplemented by additional information on dose, method of surfactant administration and dosing frequency to assess whether the dose and method of administration of surfactant given to preterm infants with respiratory distress syndrome (RDS) affects neonatal outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The rationale for this study is the clinical relevance of understanding whether surfactant dose affects neonatal outcomes in infants with RDS who are treated in the immediate postnatal period.

In a research environment, the dose of surfactant is rigorously controlled, usually administered at a dose of 100mg/kg or 200mg/kg. In clinical practice, clinicians more frequently follow the 'whole vial dosing' approach, where a full vial is given aiming to get as close as possible to the desired dose. Reasons for whole vial use include reduction of waste and administration of surfactant shortly after birth where an infant's weight is unknown. It is unclear whether whole vial dosing leads to under-dosing or over-dosing and whether either situation affects outcomes.

Information regarding the dose of surfactant delivered, and the method of administration, are not currently routinely recorded in the UK.

The primary objective of the study is to compare two dosing groups (100-130 mg/kg and 170-200 mg/kg) in terms of the proportions of infants who require mechanical ventilation within four days of birth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Distress Syndrome Bronchopulmonary Dysplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High dose surfactant

Infants who receive a first dose of surfactant between 170 and 200 mg/kg

No interventions assigned to this group

Low dose surfactant

Infants who receive a first dose of surfactant between 100 and 130 mg/kg

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \<37 weeks gestational age Requiring surfactant for Respiratory Distress Syndrome Record of birth weight available Born after study initiation

Exclusion Criteria

* 37 weeks gestation age or above Parental opt-out
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Leeds Teaching Hospitals NHS Trust

OTHER

Sponsor Role collaborator

Imperial College London

OTHER

Sponsor Role collaborator

Chiesi UK

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kevin Goss, MBBS

Role: PRINCIPAL_INVESTIGATOR

Leeds Teaching Hospitals NHS Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

William Harvey Hospital

Ashford, Kent, United Kingdom

Site Status

Birmingham Women's Hospital

Birmingham, , United Kingdom

Site Status

Birmigham Heartlands Hospital

Birmingham, , United Kingdom

Site Status

Royal Bolton Hospital

Bolton, , United Kingdom

Site Status

Bradford Royal Infirmary

Bradford, , United Kingdom

Site Status

Burnley General Hospital

Burnley, , United Kingdom

Site Status

The Rosie Hospital

Cambridge, , United Kingdom

Site Status

St Peter's Hospital

Chertsey, , United Kingdom

Site Status

University Hospital Coventry

Coventry, , United Kingdom

Site Status

Hull Royal Infirmary

Hull, , United Kingdom

Site Status

Leeds General Infirmary

Leeds, , United Kingdom

Site Status

Leicester Royal Infirmary

Leicester, , United Kingdom

Site Status

Liverpool Women's Hospital

Liverpool, , United Kingdom

Site Status

Homerton Hospital

London, , United Kingdom

Site Status

University College Hospital

London, , United Kingdom

Site Status

Guy's and St Thomas' Hospital

London, , United Kingdom

Site Status

Chelsea and Westminster Hospital

London, , United Kingdom

Site Status

St Mary's Hospital

Manchester, , United Kingdom

Site Status

Wythenshawe Hospital

Manchester, , United Kingdom

Site Status

The James Cook Hospital

Middlesbrough, , United Kingdom

Site Status

University Hospital of North Tees

Middlesbrough, , United Kingdom

Site Status

Royal Victoria Infirmary

Newcastle, , United Kingdom

Site Status

Norfolk and Norwich University Hospital

Norwich, , United Kingdom

Site Status

Queens Medical Centre

Nottingham, , United Kingdom

Site Status

Royal Oldham Hospital

Oldham, , United Kingdom

Site Status

John Radcliffe Hospital

Oxford, , United Kingdom

Site Status

Queen Alexandra Hospital

Portsmouth, , United Kingdom

Site Status

Jessop Wing

Sheffield, , United Kingdom

Site Status

Princess Anne Hospital

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Goss KCW, Gale C, Malone R, Longford N, Ratcliffe K, Modi N. Effect of surfactant dose on outcomes in preterm infants with respiratory distress syndrome: the OPTI-SURF study protocol. BMJ Open. 2020 Dec 12;10(12):e038959. doi: 10.1136/bmjopen-2020-038959.

Reference Type DERIVED
PMID: 33310795 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

36652

Identifier Type: OTHER

Identifier Source: secondary_id

IRAS 237111

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Baby Lung Study
NCT05152316 COMPLETED
Aerosolized Surfactant in Neonatal RDS
NCT02294630 COMPLETED PHASE1/PHASE2